Status:
COMPLETED
Dalfampridine and Gait in Spinocerebellar Ataxias
Lead Sponsor:
University of Florida
Collaborating Sponsors:
Acorda Therapeutics
Conditions:
Spinocerebellar Ataxias Type 1
Spinocerebellar Ataxias Type 2
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Investigators expect there will be improvement in walking speed and steadiness after taking Dalfampridine, thereby improving activities of daily living and enhancing social and occupational functions ...
Detailed Description
Twenty spinocerebellar ataxia patients will be randomized to receive either Dalfampridine or placebo over a total period of 10 weeks. After entering the study, patients will return every 2 weeks for e...
Eligibility Criteria
Inclusion
- Individuals at age 18 years or older.
- Individuals who can provide the informed consent
- Genetic confirmed definite spinocerebellar ataxias (SCA)
- Able to complete two trials of the timed 25-foot walk at screening
Exclusion
- Patients who has severe ataxia and unable to ambulate.
- Any orthopedic condition that would affect motor performance.
- Patients with secondary ataxia from general medical disorders
- Individuals who have major psychiatric disorders that prevents compliance
- History of epilepsy
- Patients with active drug or alcohol use or dependence that would interfere with adherence to study requirements
- Inability or unwillingness of subject or legal guardian/representative to give written informed consent.
Key Trial Info
Start Date :
February 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01811706
Start Date
February 1 2013
End Date
December 1 2013
Last Update
January 12 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Florida
Gainesville, Florida, United States, 32607